Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag vs Rituximab in Second-Line ITP
NCT07051915Phase 3Not yet recruiting
- Sponsor
- Ostfold Hospital Trust
- Start
- Sep 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of avatrombopag in immune thrombocytopenia (ITP), sponsored by Ostfold Hospital Trust. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
avatrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07051915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07051915.